{
  "schemaVersion" : 2,
  "registerId" : "F2018C00653",
  "instrumentNumber" : "59/2017",
  "citation" : "Statement of Principles concerning substance use disorder (Reasonable Hypothesis) (No. 59 of 2017)",
  "conditionName" : "substance use disorder",
  "effectiveFrom" : "2017-12-04",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ ],
  "onsetFactors" : [ {
    "paragraph" : "9(1)",
    "text" : "having a clinically significant disorder of mental health as specified at\r\nthe time of the clinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "clinically significant disorder of mental health as specified",
      "definition" : "means one of\r\nthe following conditions, which is of sufficient severity to warrant ongoing\r\nmanagement:\r\n(a) acute stress disorder;\r\n(b) adjustment disorder;\r\n(c) agoraphobia;\r\n(d) alcohol use disorder;\r\n(e) Alzheimer-type dementia;\r\n(f) anxiety disorder;\r\n(g) attention-deficit/hyperactivity disorder;\r\n(h) bipolar disorder;\r\n(i) conduct disorder;\r\n(j) depressive disorder;\r\n(k) eating disorder;\r\n(l) gambling disorder;\r\n(m) gender dysphoria;\r\n(n) insomnia disorder;\r\n(o) obsessive-compulsive disorder;\r\n(p) panic disorder;\r\n(q) paraphilic disorder;\r\n(r) personality disorder;\r\n(s) posttraumatic stress disorder;\r\n(t) schizophrenia;\r\n(u) sexual dysfunction;\r\n(v) social anxiety disorder;\r\n(w) somatic symptom disorder;\r\n(x) specific phobia; or\r\n(y) vascular dementia.\r\nNote 1: \"Management\" of the condition may involve regular visits (for example, at least monthly) to a\r\npsychiatrist, counsellor or general practitioner.\r\nNote 2: To \"warrant ongoing management\" does not require that any actual management was received\r\nor given for the condition."
    } ]
  }, {
    "paragraph" : "9(2)",
    "text" : "experiencing a category 1A stressor within the five years before the\r\nclinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 1A stressor",
      "definition" : "means one of the following severe traumatic events:\r\n(a) experiencing a life-threatening event;\r\n(b) being subject to a serious physical attack or assault including rape and\r\nsexual molestation; or\r\n(c) being threatened with a weapon, being held captive, being kidnapped\r\nor being tortured."
    } ]
  }, {
    "paragraph" : "9(3)",
    "text" : "experiencing a category 1B stressor within the five years before the\r\nclinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 1B stressor",
      "definition" : "means one of the following severe traumatic events:\r\n(a) killing or maiming a person;\r\n(b) being an eyewitness to a person being killed or critically injured;\r\n(c) being an eyewitness to atrocities inflicted on another person;\r\n(d) participating in the clearance of a corpse or a critically injured\r\ncasualty; or\r\n(e) viewing a corpse or a critically injured casualty as an eyewitness.\r\nNote: corpse and eyewitness are also defined in the Schedule 1 - Dictionary."
    } ]
  }, {
    "paragraph" : "9(4)",
    "text" : "experiencing the death of a significant other within the five years\r\nbefore the clinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "significant other",
      "definition" : "means a person who has a close family bond or a close\r\npersonal relationship and is important or influential in one's life."
    } ]
  }, {
    "paragraph" : "9(5)",
    "text" : "having a medical or psychiatric condition for which a substance was\r\nmedically prescribed, at the time of the clinical onset of substance use\r\ndisorder, where the substance use disorder involves one or more agents\r\nfrom the same pharmacological class as the prescribed medication",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    } ]
  }, {
    "paragraph" : "9(6)",
    "text" : "experiencing severe childhood abuse before the clinical onset of\r\nsubstance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "severe childhood abuse",
      "definition" : "means:\r\n(a) serious physical, emotional, psychological or sexual harm whilst a\r\nchild aged under 16 years; or\r\n(b) neglect involving a serious failure to provide the necessities for health,\r\nphysical and emotional development, or wellbeing whilst a child aged\r\nunder 16 years;\r\nwhere such serious harm or neglect has been perpetrated by a parent, a care\r\nprovider, an adult who works with or around that child, or any other adult in\r\ncontact with that child."
    } ]
  }, {
    "paragraph" : "9(7)",
    "text" : "having a medical illness or injury which is life-threatening or which\r\nresults in serious physical or cognitive disability, within the five years\r\nbefore the clinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    } ]
  }, {
    "paragraph" : "9(8)",
    "text" : "experiencing a category 2 stressor within the one year before the\r\nclinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 2 stressor",
      "definition" : "means one of the following negative life events, the\r\neffects of which are chronic in nature and cause the person to feel ongoing\r\ndistress, concern or worry:\r\n(a) being socially isolated and unable to maintain friendships or family\r\nrelationships, due to physical location, language barriers, disability, or\r\nmedical or psychiatric illness;\r\n(b) experiencing a problem with a long-term relationship including the\r\nbreak-up of a close personal relationship, the need for marital or\r\nrelationship counselling, marital separation or divorce;\r\n(c) having concerns in the work or school environment including ongoing\r\ndisharmony with fellow work or school colleagues, perceived lack of\r\nsocial support within the work or school environment, perceived lack\r\nof control over tasks performed and stressful workloads, or\r\nexperiencing bullying in the workplace or school environment;\r\n(d) experiencing serious legal issues including being detained or held in\r\ncustody, ongoing involvement with the police concerning violations of\r\nthe law, or court appearances associated with personal legal problems;\r\n(e) having severe financial hardship including loss of employment, long\r\nperiods of unemployment, foreclosure on a property or bankruptcy;\r\n(f) having a family member or significant other experience a major\r\ndeterioration in their health; or\r\n(g) being a full-time caregiver to a family member or significant other\r\nwith a severe physical, mental or developmental disability.\r\nNote: significant other is also defined in the Schedule 1 - Dictionary."
    } ]
  }, {
    "paragraph" : "9(9)",
    "text" : "having persistent pain of at least three months duration at the time of\r\nthe clinical onset of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "persistent pain",
      "definition" : "means:\r\n(a) continuous pain; or\r\n(b) almost continuous pain; or\r\n(c) frequent, severe, intermittent pain;\r\nwhich is severe enough to interfere with usual work or leisure activities or\r\nactivities of daily living."
    } ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "9(10)",
    "text" : "having a clinically significant disorder of mental health as specified at\r\nthe time of the clinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "clinically significant disorder of mental health as specified",
      "definition" : "means one of\r\nthe following conditions, which is of sufficient severity to warrant ongoing\r\nmanagement:\r\n(a) acute stress disorder;\r\n(b) adjustment disorder;\r\n(c) agoraphobia;\r\n(d) alcohol use disorder;\r\n(e) Alzheimer-type dementia;\r\n(f) anxiety disorder;\r\n(g) attention-deficit/hyperactivity disorder;\r\n(h) bipolar disorder;\r\n(i) conduct disorder;\r\n(j) depressive disorder;\r\n(k) eating disorder;\r\n(l) gambling disorder;\r\n(m) gender dysphoria;\r\n(n) insomnia disorder;\r\n(o) obsessive-compulsive disorder;\r\n(p) panic disorder;\r\n(q) paraphilic disorder;\r\n(r) personality disorder;\r\n(s) posttraumatic stress disorder;\r\n(t) schizophrenia;\r\n(u) sexual dysfunction;\r\n(v) social anxiety disorder;\r\n(w) somatic symptom disorder;\r\n(x) specific phobia; or\r\n(y) vascular dementia.\r\nNote 1: \"Management\" of the condition may involve regular visits (for example, at least monthly) to a\r\npsychiatrist, counsellor or general practitioner.\r\nNote 2: To \"warrant ongoing management\" does not require that any actual management was received\r\nor given for the condition."
    } ]
  }, {
    "paragraph" : "9(11)",
    "text" : "experiencing a category 1A stressor within the five years before the\r\nclinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 1A stressor",
      "definition" : "means one of the following severe traumatic events:\r\n(a) experiencing a life-threatening event;\r\n(b) being subject to a serious physical attack or assault including rape and\r\nsexual molestation; or\r\n(c) being threatened with a weapon, being held captive, being kidnapped\r\nor being tortured."
    } ]
  }, {
    "paragraph" : "9(12)",
    "text" : "experiencing a category 1B stressor within the five years before the\r\nclinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 1B stressor",
      "definition" : "means one of the following severe traumatic events:\r\n(a) killing or maiming a person;\r\n(b) being an eyewitness to a person being killed or critically injured;\r\n(c) being an eyewitness to atrocities inflicted on another person;\r\n(d) participating in the clearance of a corpse or a critically injured\r\ncasualty; or\r\n(e) viewing a corpse or a critically injured casualty as an eyewitness.\r\nNote: corpse and eyewitness are also defined in the Schedule 1 - Dictionary."
    } ]
  }, {
    "paragraph" : "9(13)",
    "text" : "experiencing the death of a significant other within the five years\r\nbefore the clinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "significant other",
      "definition" : "means a person who has a close family bond or a close\r\npersonal relationship and is important or influential in one's life."
    } ]
  }, {
    "paragraph" : "9(14)",
    "text" : "experiencing severe childhood abuse before the clinical worsening of\r\nsubstance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "severe childhood abuse",
      "definition" : "means:\r\n(a) serious physical, emotional, psychological or sexual harm whilst a\r\nchild aged under 16 years; or\r\n(b) neglect involving a serious failure to provide the necessities for health,\r\nphysical and emotional development, or wellbeing whilst a child aged\r\nunder 16 years;\r\nwhere such serious harm or neglect has been perpetrated by a parent, a care\r\nprovider, an adult who works with or around that child, or any other adult in\r\ncontact with that child."
    } ]
  }, {
    "paragraph" : "9(15)",
    "text" : "having a medical illness or injury which is life-threatening or which\r\nresults in serious physical or cognitive disability, within the five years\r\nbefore the clinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    } ]
  }, {
    "paragraph" : "9(16)",
    "text" : "experiencing a category 2 stressor within the one year before the\r\nclinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "category 2 stressor",
      "definition" : "means one of the following negative life events, the\r\neffects of which are chronic in nature and cause the person to feel ongoing\r\ndistress, concern or worry:\r\n(a) being socially isolated and unable to maintain friendships or family\r\nrelationships, due to physical location, language barriers, disability, or\r\nmedical or psychiatric illness;\r\n(b) experiencing a problem with a long-term relationship including the\r\nbreak-up of a close personal relationship, the need for marital or\r\nrelationship counselling, marital separation or divorce;\r\n(c) having concerns in the work or school environment including ongoing\r\ndisharmony with fellow work or school colleagues, perceived lack of\r\nsocial support within the work or school environment, perceived lack\r\nof control over tasks performed and stressful workloads, or\r\nexperiencing bullying in the workplace or school environment;\r\n(d) experiencing serious legal issues including being detained or held in\r\ncustody, ongoing involvement with the police concerning violations of\r\nthe law, or court appearances associated with personal legal problems;\r\n(e) having severe financial hardship including loss of employment, long\r\nperiods of unemployment, foreclosure on a property or bankruptcy;\r\n(f) having a family member or significant other experience a major\r\ndeterioration in their health; or\r\n(g) being a full-time caregiver to a family member or significant other\r\nwith a severe physical, mental or developmental disability.\r\nNote: significant other is also defined in the Schedule 1 - Dictionary."
    } ]
  }, {
    "paragraph" : "9(17)",
    "text" : "having persistent pain of at least three months duration at the time of\r\nthe clinical worsening of substance use disorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    }, {
      "term" : "persistent pain",
      "definition" : "means:\r\n(a) continuous pain; or\r\n(b) almost continuous pain; or\r\n(c) frequent, severe, intermittent pain;\r\nwhich is severe enough to interfere with usual work or leisure activities or\r\nactivities of daily living."
    } ]
  }, {
    "paragraph" : "9(18)",
    "text" : "inability to obtain appropriate clinical management for substance use\r\ndisorder",
    "definedTerms" : [ {
      "term" : "substance",
      "definition" : "means any of the following s, alone or in combination:\r\n(a) amphetamine-type s;\r\n(b) cannabis and cannabis derivatives;\r\n(c) cocaine;\r\n(d) hallucinogens, including phencyclidine and pharmacologically similar\r\ns;\r\n(e) hydrocarbon-based inhalants;\r\n(f) opioids, and opioid derivatives and synthetic opioids with morphine-\r\nlike effects;\r\n(g) sedatives, hypnotics and anxiolytics, including barbiturates,\r\nnonbarbiturate sedatives and benzodiazepines, and tranquillisers with\r\nsimilar effect; or\r\n(h) tobacco.\r\n use disorder—see subsection 7(2)."
    } ]
  } ]
}